Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 1.15% 88.00 452,160 15:10:43
Bid Price Offer Price High Price Low Price Open Price
87.00 89.00 88.00 86.50 87.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 30.08 3.28 2.74 32.1 111
Last Trade Time Trade Type Trade Size Trade Price Currency
16:04:50 O 126,000 87.00 GBX

Venture Life (VLG) Latest News

More Venture Life News
Venture Life Investors    Venture Life Takeover Rumours

Venture Life (VLG) Discussions and Chat

Venture Life Forums and Chat

Date Time Title Posts
15/4/202121:33Venture Life Group plc977
02/1/202108:45ValueGrowth Investing35,063
02/4/201510:58Venture Life Group - Intro video-

Add a New Thread

Venture Life (VLG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Venture Life trades in real-time

Venture Life (VLG) Top Chat Posts

Venture Life Daily Update: Venture Life Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 87p.
Venture Life Group Plc has a 4 week average price of 81p and a 12 week average price of 78p.
The 1 year high share price is 117p while the 1 year low share price is currently 47.50p.
There are currently 125,810,530 shares in issue and the average daily traded volume is 528,262 shares. The market capitalisation of Venture Life Group Plc is £110,713,266.40.
lammylover: Looks like we may have to wait for news of acquisitions, but that's fine. I'd rather the Board spent longer doing their due diligence and getting a complementary business at the right price, rather than rushing to use the fund raise monies. This is a strong company in growth sector which should accelerate its performance as CV19 lockdown lifts and customers return to the high street. I'd expect Simon Thompson in IC to continue to rate a Buy, based on LY results. Share price will probably bounce over 90p as soon as he lists it on line / via Investors Chronicle magazine. Happy to hold for further gains. Rich
rivaldo: Good news for VLG from Alliance Pharma's 2020 results today - APH did OK overall, but Kelo-cote outperformed, particularly from Q2 onwards (which was when VLG began production): "Kelo-cote - scar prevention and treatment We were particularly pleased with the performance of Kelo-cote, which delivered good growth in 2020, continuing the trend from 2019, with sales up 12% to GBP34.7m (2019: GBP31.0m), due to further strong demand from China from the second quarter onwards as local lockdown restrictions eased. Across the rest of the APAC region, ongoing local lockdown restrictions in response to the pandemic have had a more sustained impact on the brand's performance, likewise in South America and some countries within EMEA. Nevertheless, we expect sales across all these regions to return strongly once lockdown restrictions are eased."
simon gordon: Mark Slater talking about his methodology the other day: Trustnet - 28/1/21 ...Slater, who seeks growth at an equitable price, is the son of renowned UK investor Jim Slater, who died in 2015 and coined the “Zulu Principle”, a strategy that combines growth, value, quality, and momentum factors. Using price-to-earnings growth as a measure, the strategy compares a company’s forecast price-to-earnings ratio with its forecast earnings-per-share growth rate, which is currently deployed as a screening mechanism in the fund. “We’re not interested in price-to-book,” said Slater, highlighting a three-pronged approach to screening stocks. “We want companies that are growing at a double-digit rate in earnings terms,” he said. “Secondly, [we consider whether you] can you buy that growth cheaply, and the third is profit conversion into cash. Hence price-to-cash flow is important as we want the cash flow per share to be in excess of earnings per share.” Slater explained those three screens eliminate 95 per cent of the UK market and would do something similar if applied to most markets. “Most companies are not growing,” said the manager. “Or if they are, they’re very expensive or they’re not generating cash.” A shortlist is collated which then requires further analysis into how reliable that growth rate is. “Then the work goes from being entirely quantitative to entirely qualitative,” he said. “Is there a tangible tailwind which his driving that growth? It’s why our businesses are quite niche; they’re doing one or two things but are doing them exceptionally well.” Https://
qs99: Yup, thanks Riv, just a shame VLG share price heading in the wrong direction! Let's hope we get some news soon on trading, deals etc
rivaldo: Hi QS99, HNY to you too! I stopped working over Xmas/New Year a long time ago when I started doing this lark, which is much more pleasant and has far shorter hours.... Happy to hold VLG for the long-term - acquisitions will happen when they happen, and in the meantime VLG are trading very well anyway. The share price has roughly tripled in the last year, and imo there's still plenty of upside.
rivaldo: Good to see the price rising again. QS99, I completely agree that DD is so much easier nowadays. But surely in VLG's line of work they need to inspect the manufacturing facilities, review the distribution networks etc - corners can't be cut on these things. It's only been just over a month since VLG even announced the Placing and Offer, so it wouldn't surprise me if COVID had caused timelines on these things to slip a little. Obviously I hope I'm wrong! But I fully expect there to be news soon - be it trading or acquisitions - and when it happens the share price is likely to rise nicely imo.
discodave45: PS I'm also a tad cynical on the sequence of events prior to the announcement (Friday afternoon ffs) of the placing, namely that a couple of days beforehand they updated the market on the clinical trial (to boost the share price) and on the day the placing was announced a known ex associate and major shareholder sold some shares (Dr Flynn)...just coincidence?.....not to mention a couple of the BOD selling.
rivaldo: Great move by VLG to raise £34m at this time to take advantage of distressed sellers - and it seems they already have three well advanced potential acquisitions which would cost £25m-£30m and likely be extremely earnings-enhancing, particularly as the products can be produced internally. As co-founders of VLG in 2010 I'm not too bothered about the CEO and Collins selling roughly half their shares into liquidity, and they can't sell any more for at least two years. The 90p price is disappointing overall - but at least us PIs will get the chance to participate for another £2m. I'm pretty sure this fundraising would have been launched a little while ago, which would account (in the traditional way of the City....) for the share price drop to 90p or so. Today's 90p price is the result.
rivaldo: Good to see VLG newly tipped on Investors' Champion - subscriber-only though: Https:// "A reasonably valued healthcare company, there must be a catch! (Updated) 18/11/2020 · Venture Life Group PLC (VLG) Many healthcare companies, especially with anything relating to aiding Covid-19, have benefited from a strong share price over the pandemic and it is rare to find something of seemingly reasonable value. The shares received another boost on news that its mouthwash might be effective against COVID-19. Check out our updated research here. Founded in 2010, Venture Life Group (LON:VLG) is an international consumer healthcare company focused on developing and manufacturing non-drug self-care products for the ageing population, which consumers can buy without prescription. The Group's manufacturing is based in Italy, where a 5,500m² factory is being expanded to produce up to 55 million units per annum by the end of the year, producing both Venture Life's own brands as well as products for others as a contract manufacturer. With over 35 years of experience, the site boasts exciting development capabilities thanks to superior laboratory facilities and knowledge of the market. The Group has 10 branded products, covering…"
redartbmud: tlatsatt Extreme volatility isn't too good for my constitution. Big moves, on the back of no news, especially those to the downside, do challenge one's resolve. Rsw is a good case study, the other way. The last set of results were not good, and global market conditions have deteriorated since, as the lockdown took hold. Logic says that their business to supply capital and revenue items to manufacturing industry, that is currently partially closed down or at best operating well below capacity, should result in further deterioration before the situation improves. Based on subdued profitability, the share price ought to be significantly ahead of resukts and forecasts. If that is the case, the sometimes 100p daily share price increase, on an already rising share price, is irrational. red
Venture Life share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210419 02:04:33